In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease
Top Cited Papers
- 1 July 2006
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 44 (1), 27-33
- https://doi.org/10.1002/hep.21223
Abstract
In patients with nonalcoholic fatty liver disease (NAFLD), a liver biopsy remains the only reliable way to differentiate simple steatosis from nonalcoholic steatohepatitis (NASH). Noninvasive methods are urgently needed. Increasing evidence suggests hepatocyte apoptosis is a key mediator of liver injury in NAFLD. The aim of this study was to quantify hepatocyte apoptosis in plasma from patients with NAFLD and correlate it with histological severity. Plasma was obtained from 44 consecutive patients with suspected NAFLD at the time of liver biopsy. Histology was assessed blindly. Caspase‐3–generated cytokeratin‐18 fragments were measured in situ via immunohistochemistry and in vivo using a novel enzyme‐linked immunosorbent assay. Plasma cytokeratin‐18 fragments were markedly increased in patients with NASH compared with patients with simple steatosis or normal biopsies (median [interquartile range]: 765.7 U/L [479.6–991.1], 202.4 U/L [160.4–258.2], 215.5 U/L [150.2–296.2], respectively; P < .001). Cytokeratin‐18 fragment levels independently predicted NASH (OR 1.95; 95% CI 1.18–3.22; P = .009 for every 50 U/L increase). A cutoff value of 395 U/L calculated using the receiver operating characteristic curve approach showed a specificity of 99.9%, a sensitivity of 85.7%, and positive and negative predictive values of 99.9% and 85.7%, respectively, for the diagnosis of NASH. In conclusion, these findings strongly suggest that determination of hepatocyte caspase activation in the blood is a strong and independent predictor of NASH in human subjects. These data highlight the potential usefulness of this test as a noninvasive diagnostic means of determining histological disease severity in patients with NAFLD. (HEPATOLOGY 2006;44:27–33.)This publication has 23 references indexed in Scilit:
- Apoptosis and Bcl-2 expression in the livers of patients with steatohepatitisEuropean Journal of Gastroenterology & Hepatology, 2006
- Nonalcoholic fatty liver disease in the pediatric population: a reviewCurrent Opinion in Pediatrics, 2005
- The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort StudyGastroenterology, 2005
- Apoptosis in alcoholic and nonalcoholic steatohepatitisFrontiers in Bioscience-Landmark, 2005
- Hepatocyte Apoptosis, Expression of Death Receptors, and Activation of NF-κB in the Liver of Nonalcoholic and Alcoholic Steatohepatitis PatientsThe American Journal of Gastroenterology, 2004
- Free fatty acids promote hepatic lipotoxicity by stimulating TNF-α expression via a lysosomal pathwayHepatology, 2004
- Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitisGastroenterology, 2003
- Nonalcoholic Fatty Liver DiseaseThe New England Journal of Medicine, 2002
- Detection of elevated caspase activation and early apoptosis in liver diseasesEuropean Journal of Cell Biology, 2001
- Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severityGastroenterology, 1999